ALIVUS LIFE SCIENCES LIMITED
₹1,407.80+₹10.05 (+0.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹10,777 Cr
- P/E
- 20.3x
- EV / EBITDA
- 15.2x
- Revenue
- ₹2,387 Cr
- Net margin
- 20.6%
- ROCE
- 28.7%
Price chart
Technical chartScreen technicals →+54.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +2.1%
- 3M
- +28.5%
- 6M
- +35.7%
- 1Y
- +54.7%
- 5Y
- +123.1%
52-week range
Day change +₹10.05 (+0.7%) from ₹1,398 to ₹1,408 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ALIVUS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.2%
Concerns1
- Negative free cash flow (₹224 Cr)
Rule-based from financial data. Not advice.
About the company
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally.
Read moreShow less
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
- Sector
- Healthcare
- Shares outstanding
- 12.3 Cr shares
- ISIN
- INE03Q201024
- BSE code
- 543322
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹10,777 Cr
- P/E
- 20.3x
- P/B
- 3.6x
- EV / EBITDA
- 15.2x
- EV / Sales
- 4.6x
- P/S
- 4.7x
- Earnings yield
- 4.9%
- 52-week high
- ₹1,443.55
- 52-week low
- ₹861.80
Profitability
- Operating margin
- 29.6%
- Net margin
- 20.6%
- EBITDA margin
- 30.0%
- ROE
- 20.2%
- ROCE
- 28.7%
- ROA
- 16.5%
- Dividend payout
- 59.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 1.7%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,387 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.2%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹686 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.2%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹414 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 35.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹230 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.5%
Solvency and efficiency
- Current ratio
- 3.87
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- Debt / EBITDA
- 0.02
- Interest coverage
- 337.50
- Financial leverage
- 1.22
- CFO / Net profit
- 0.88
- Cash / Market cap
- 18.0%
- Cash per share
- ₹157.79
- Asset turnover
- 0.80
- Fixed asset turnover
- 2.84
- Capital intensity
- 0.35
- Debtor days
- 122 days
- Inventory turnover
- 1.45
- Cash conversion cycle
- 235 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹20 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,703 Cr |
| Sales | Operating profit | ₹684 Cr |
| Operating profit | Interest | ₹2 Cr |
| Operating profit | Depreciation | ₹61 Cr |
| Operating profit | Profit before tax | ₹621 Cr |
| Other income | Profit before tax | ₹33 Cr |
| Profit before tax | Tax and other | ₹168 Cr |
| Profit before tax | Net profit | ₹486 Cr |
Revenue and net profit
Revenue grew 4.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,885 Cr | ₹352 Cr |
| FY2022 | ₹2,123 Cr | ₹419 Cr |
| FY2023 | ₹2,161 Cr | ₹467 Cr |
| FY2024 | ₹2,283 Cr | ₹471 Cr |
| FY2025 | ₹2,387 Cr | ₹486 Cr |
Cash flows
FY2025: ₹392 Cr from operations, -₹224 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹388 Cr | ₹319 Cr |
| FY2022 | ₹598 Cr | ₹476 Cr |
| FY2023 | ₹306 Cr | ₹159 Cr |
| FY2024 | ₹414 Cr | ₹298 Cr |
| FY2025 | ₹392 Cr | -₹224 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹2,387 Cr+4.6%1Y
- Net profit
- ₹486 Cr+3.2%1Y
- Cash from operations
- ₹392 Cr
- Free cash flow
- -₹224 Cr-175.2%1Y
- Revenue CAGR, 5Y
- 8.2%
- EBITDA CAGR, 5Y
- 7.2%
- Net profit CAGR, 5Y
- 8.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,387 Cr | ₹684 Cr | — | ₹486 Cr | ₹392 Cr | -₹224 Cr | 17.2% | +4.6% | +3.2% |
Monthly returns
Month-by-month returns of ALIVUS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹3,411 Cr |
| Equity capital | ₹25 Cr |
| Reserves | ₹2,793 Cr |
| Borrowings | ₹57 Cr |
| Other liabilities | ₹537 Cr |
| Assets | ₹3,411 Cr |
| Fixed assets | ₹955 Cr |
| Capital work in progress | ₹102 Cr |
| Investments | ₹478 Cr |
| Other assets | ₹1,877 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ALIVUS trades at 20.3x earnings against a peer median of 52.6x (a 61% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ALIVUS LIFE SCIENCES LIMITEDALIVUSthis companyP/E ↓ discount | ₹10,777 Cr | 20.3x | 3.6x | 20.2% | 15.2x |
| Rainbow Children's Medicare LimitedRAINBOW | ₹12,756 Cr | 51.8x | 8.1x | 16.7% | 29.5x |
| RUBICON RESEARCH LIMITEDRUBICON | ₹11,141 Cr | 65.0x | — | 5.0% | 115.2x |
| Vijaya Diagnostic Centre LimitedVIJAYA | ₹10,297 Cr | 69.2x | 12.1x | 17.6% | 45.6x |
| Metropolis Healthcare LimitedMETROPOLIS | ₹9,882 Cr | 74.0x | 7.4x | 11.3% | 36.5x |
| Sanofi Consumer Healthcare India LimitedSANOFICONR | ₹9,742 Cr | 45.3x | 37.8x | — | — |
| JYOTHY LABS LIMITEDJYOTHYLAB | ₹9,555 Cr | 27.2x | 6.6x | 32.4% | 17.6x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ALIVUS since 1 January, against earlier years.
Historical volatility
ALIVUS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 31.0% |
| FY2022 | 29.0% |
| FY2023 | 30.0% |
| FY2024 | 30.0% |
| FY2025 | 29.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹2,387 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹1,702 Cr |
| Operating profitOperating Profit | ₹684 Cr |
| Other income and charges | |
| Profit before tax | ₹654 Cr |
| Tax | |
| Net profitNet Profit | ₹486 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹3,411 Cr |
| Equity capitalEquity Capital | ₹25 Cr |
| Reserves | ₹2,793 Cr |
| Borrowings | ₹57 Cr |
| Other liabilitiesOther Liabilities | ₹537 Cr |
| AssetsTotal Assets | ₹3,411 Cr |
| Fixed assetsFixed Assets | ₹955 Cr |
| Capital work in progressCWIP | ₹102 Cr |
| Investments | ₹478 Cr |
| Other assetsOther Assets | ₹1,877 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹392 Cr |
| Investing cash flowCash from Investing Activity | -₹616 Cr |
| Financing cash flowCash from Financing Activity | -₹6 Cr |
| Change in cashNet Cash Flow | -₹230 Cr |
Learn while you research
Academy chapters picked for ALIVUS LIFE SCIENCES LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read